Hair loss - one of the worst side effects of cancer treatment. Scientists know that the cooling of the human scalp can prevent a significant loss of hair duringchemotherapy. In 2015, the Office of the US Food and Drug Administration approved a cooling device called DigniCap for women with breast cancer. Cap has been tested in clinical trials at UCLA under the direction of Dr. Sara Hurwitz, Director of Hematology and Oncology program for breast cancer in the Comprehensive Cancer Center.
Two studies published in the Journal of the American Medical Association this month, showed that the cooling cap is effective. The results showed that hair loss has decreased by 50 percent, which was one of the ways to overcome the visible sign of treatment.
The idea of cooling the scalp during chemotherapy to reduce hair loss appeared for a long time, more than three decades ago. This is the first device that are approved by the Food and Drug Administration.
The researchers recorded and treated several patients who took standard chemotherapy in the early stages of breast cancer.
How does the cooling cap? Cooling the scalp slows blood flow to the hair follicles during chemotherapy infusion. This reduces the toxic effects of treatments on the hair follicle, thereby limiting the loss of hair. Some devices use the ice caps, but they are difficult to store and manage. The new device is a tightly fitting lid, similar to a swimming cap, which is attached to a cooling machine and worn during the chemotherapy and within an hour or two after it.
Hair loss in the treatment of cancer has a significant impact on the quality of life for many women with early stage breast cancer. Reduction or prevention of hair loss will reduce the emotional stress associated with the diagnosis of cancer.
However, hair loss in most patients with scalp cooling is not completely stopped. Compared with women who did not use the cooling of the scalp, in women who have tried this product after chemotherapy hair looks normal and recover faster.
In clinical tests are evaluated, and other devices which will be used by patients of the male sex.